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One of the classes of compounds with well
documented anticonvulsant activity are spirosuccin-
imide derivatives (1-4). Based on this facts, in our
earlier studies we have described anticonvulsant
properties of many 2-azaspiro[4.4]nonane- and
[4.5]decane-1,3-diones differently substituted at the
imide nitrogen atom (5-10). The structure-activity
relationship studies conducted with these groups of
compounds revealed that their activity were highly
dependend on the size of the cycloalkyl system
attached to the C3 spiro carbon atom and the kind
and position of the substituents at the aromatic ring.
Moreover, it was proved that the imine (-NH-) link-
er joining the endocyclic nitrogen atom and aromat-
ic moiety increased the anticonvulsant activity in
comparison to respective methylene (-CH2-) ana-
logues (6). Among those derivatives the most active
was N-phenylamino-2-azaspiro[4.4]nonane-1,3-
dione [I] which structure is presented below:
The change of the size of a cycloalkyl unit to
cyclohexane resulted in less active N-phenylamino-
2-azaspiro[4.5]decane-1,3-dione:
Regarding the above molecules as lead struc-
tures, in this work we have designed, synthesized
and tested for their anticonvulsant activity a new
series of 2-azaspiro[4.4]nonane-, 2-azaspiro[4.5]
decane- and 6-methyl-2-azaspiro[4.5]decane-1,3-
diones with phenylamino moiety at the nitrogen
atom. On the other hand, to investigate the influence
of the cycloalkyl system, attached to the succin-
imide through the C3 spiro carbon atom, on the anti-
convulsant activity, we obtained a series of deriva-
tives with cyclohexyl moiety as a flexible fragment
at 3-position of pyrrolidine-2,5-dione ring.
The starting cyclopentane-, cyclohexane-, (2-
methylcyclohexane)-1-carboxy-1-acetic acids and
2-cyclohexylsuccinic acid were prepared as reported
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Abstract: To continue our systematic SAR studies a series of N-phenylamino derivatives of 2-aza-
spiro[4.4]nonane-, 2-azaspiro[4.5]decane-, 6-methyl-2-azaspiro[4.5]decane-1,3-dione and 3-cyclohexylpyrroli-
dine-2,5-dione were synthesized and tested for their anticonvulsant activity in the maximum electroshock
seizure (MES) and subcutaneous metrazole seizure threshold (sc. Met) tests. Among those molecules the most
potent were N-(4-methylphenyl)-amino-2-azaspiro[4.4]nonane-1,3-dione [V], N-(2-trifluoromethylphenyl)-
amino-2-azaspiro[4.4]nonane-1,3-dione [VI], N-(3-methylphenyl)-amino-2-azaspiro[4.5]decane-1,3-dione
[VIII] and N-(4-methylphenyl)-amino-6-methyl-2-azaspiro[4.5]decane-1,3-dione [XIV], which inhibited the
seizures mainly in the sc. Met test. The obtained results revealed that anticonvulsant activity depended on the
presence and the position of the methyl or trifluoromethyl groups at the aryl moiety, as well as the size and the
manner of attachment of the cycloalkyl system at the position-3 of the pyrrolidine-2,5-dione ring.
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previously (11, 12). The final compounds [III-
XVIII] were obtained in a one-pot cyclization reac-
tion of the prepared dicarboxylic acids and appro-
priately substituted phenylhydrazines by heating
them at ca. 190-200OC for 1.5 h. The synthetic pro-
cedures are shown in Schemes 1 and 2.
The 1H NMR spectra of the compounds syn-
thesized were studied and revealed a few character-
istic chemical shifts. The protons of cycloalkyl rings
were observed as multiplets within a range of 0.97-
2.17 ppm. In the series of 2-azaspiro[4.4]nonane-
and 2-azaspiro[4.5]decane-1,3-dione derivatives
[III-X] the chemical shifts of imide protons were
shown as singlets ranging from 2.65 to 2.75 ppm,
whereas in a group of 6-methyl-2-azaspiro[4.5]
decane-1,3-diones [XI-XV] appeared as doublets
within a range of 2.46-2.74 ppm. The resonance sig-
nals of protons of succinimide moiety [XVI-XVIII]
were recorded as multiplets within a range of 2.58-
2.93 ppm. For all the compounds the protons of 
-NH- linkers were observed as broad singlets rang-
ing from 6.01 to 6.60 ppm. The resonance signals of
protons of methyl groups at the aryl moiety were
recorded as singlets, depending on the position with-
in a range of 2.34-2.35 ppm, 2.27-2.28 and at 2.26
ppm for the ortho, meta and para isomers, respec-
tively. The protons of methyl groups at position-6 of
the 2-azaspiro[4.5]decane-1,3-dione moiety [XI-
XV] were shown as doublets ranging from 0.80 to
0.86 ppm. The resonance signals of aromatic pro-
tons were well separated and were observed within
a range of 6.45-7.56 ppm. For the details see Tables
2, 3 and 4.
EXPERIMENTAL
Chemistry
Melting points (m.p.) were determined with an
Electrothermal digital melting point apparatus and
are uncorrected. The chemical structures of com-
pounds were confirmed by elemental and spectral
analyses. 1H NMR spectra were obtained on a
Ring A = cyclopentane I, III-VI
Ring A = cyclohexane II, VII-X
Ring A = metylocyclohexane XI-XV
No. I*, II*, XI III, VII, XII IV, VII, XII V, IX, XIV, VI, X, XV
R H 2-CH3 3-CH3 4-CH3 2-CF3
* For physicochemical and spectral data see reference (6)
Scheme 1.
No. XVI VII VII
R H 2-CH3 4-CH3
Scheme 2.
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Varian Mercury 300 MHz spectrometer (Varian
Inc., Palo Alto, CA, USA), in CDCl3. Chemical
shifts were reported as parts per million (δ ppm)
from (CH3)4Si (TMS) as an internal standard. Signal
multiplicities are represented by the following
abbreviations: s (singlet), brs (broad singlet), d (dou-
blet), t (triplet), m (multiplet). 
Elemental analyses for C, H, N were carried
out with an Elementar Vario EL III apparatus
(Hanau, Germany), and were within ±0.4% of the
theoretical values.
The purity of the compounds was checked by
the thin-layer chromatography (TLC) performed on
Merck silica gel GF254 aluminium sheets, using the
developing system: chloroform:acetone (9:1, v/v).
Spots were detected by their absorption under UV
(254 nm) light and by visualization with 0.05 mol I2
in 10% HCl.






To a suspension of cyclopentane-, cyclohexa-
ne-, (2-methylcyclohexane)-1-carboxy-1-acetic acid
or 2-cyclohexylsuccinic acid (0.01 mol) in 10 ml of
water, the appropriately substituted phenylhy-
drazines (0.01 mol) were gradually added. The mix-
ture was heated in an oil bath and water was simul-
taneously distilled off. When the water was com-
Table 1. Physicochemical and analytical data for compounds III-XVIII
Molecular Formula Yield Analysis (calcd/found)
No.
Weight mp.[OC] %C %H %N
Rf
C15H18N2O2 51 69.74 7.02 10.84
III
258.32 170-172 69.70 6.98 10.79
0.66
C15H18N2O2 53 69.74 7.02 10.84
IV
258.32 126-128 69.71 7.00 10.80
0.73
C15H18N2O2 48 69.74 7.02 10.84
V
258.32 134-136 69.72 6.99 10.78
0.76
C15H15F3N2O2 47 57.69 4.84 8.97
VI
312.29 145-147 57.60 4.80 8.91
0.85
C16H20N2O2 54 70.56 7.40 10.29
VII
272.35 154-156 70.49 7.32 10.18
0.71
C16H20N2O2 50 70.56 7.40 10.29
VIII
272.35 131-133 70.49 7.41 10.19
0.75
C16H20N2O2 49 70.56 7.40 10.29
IX
272.35 156-158 70.52 7.42 10.20
0.80
C16H17F3O2N2 48 58.89 5.25 8.58
X
326.33 191-193 58.79 5.30 8.49
0.92
C16H20N2O2 51 70.56 7.40 10.29
XI
272.35 121-123 70.46 7.32 10.25
0.73
C17H22N2O2 53 71.30 7.74 9.78
XII
286.38 169-171 71.21 7.69 9.70
0.75
C17H22N2O2 46 71.30 7.74 9.78
XIII
286.38 152-154 71.12 7.52 9.69
0.81
C17H22N2O2 50 71.30 7.74 9.78
XIV
286.38 128-130 71.21 7.69 9.71
0.75
C17H19F3O2N2 48 59.99 5.63 8.23
XV
340.35 195-197 59.89 5.61 8.15
0.92
C16H20N2O2 54 70.56 7.40 10.29
XVI
272.35 168-170 70.45 7.42 10.17
0.83
C17H22N2O2 52 71.30 7.74 9.78
XVII
286.38 124-126 71.19 7.71 9.70
0.64
C17H22N2O2 51 71.30 7.74 9.78
XVIII
286.38 163-165 71.21 7.70 9.75
0.82
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Table 2. 1H NMR spectral data of compounds III-X
No. R 1H NMR δ (ppm)/ CDCl3
1.74-2.22 (8H, m, cyclopentane), 2.34 (3H, s, -CH3), 2.72 (2H, s, imide), 6.03
III 2-CH3 (1H, brs, -NH-), 6.47 (1H, d, Harom., J=7.95 Hz), 6.87-6.92 (1H, m, Harom.),
7.06-7.12 (2H, m, Harom.)
1.73-2.23 (8H, m, cyclopentane), 2.28 (3H, s, -CH3), 2.71 (2H, s, imide), 6.06
IV 3-CH3 (1H, brs, -NH-), 6.53-6.58 (2H, m, Harom.), 6.78-6.80 (1H, m, Harom.), 7.12
(1H, t, Harom., J=7.69 Hz)
1.71-2.21 (8H, m, cyclopentane), 2.26 (3H, s, -CH3), 2.69 (2H, s, imide), 6.06
V 4-CH3 (1H, brs, -NH-), 6.68-6.72 (2H, m, Harom.), 7.03-7.06 (2H, m, Harom.)
1.75-2.25 (8H, m, cyclopentane), 2.75 (2H, s, imide), 6.55 (1H, d, Harom.,
VI 2-CF3 J=8.20 Hz), 6.60 (1H, brs, -NH-), 7.03 (1H, t, Harom., J=7.18 Hz), 7.39 (1H, t,
Harom., J=7.18 Hz), 7.56 (1H, d, Harom., J=7.95 Hz)
1.37-1.92 (10H, m, cyclohexane), 2.34 (3H, s, -CH3), 2.69 (2H, s, imide), 6.01
VII 2-CH3 (1H, brs, -NH-), 6.45 (1H, d, Harom., J=7.44 Hz), 6.86-6.91 (1H, m, Harom.),
7.08-7.12 (2H, m, Harom.)
1.36-1.91 (10H, m, cyclohexane), 2.28 (3H, s, -CH3), 2.67 (2H, s, imide), 6.04
VIII 3-CH3 (1H, brs, -NH-), 6.52-6.57 (2H, m, Harom.), 6.77-6.80 (1H, m, Harom.), 7.11
(1H, t, Harom., J=7.82 Hz)
1.35-1.90 (10H, m, cyclohexane), 2.26 (3H, s, -CH3), 2.65 (2H, s, imide), 6.04
IX 4-CH3 (1H, brs, -NH-), 6.67-71 (2H, m, Harom.), 7.02-7.05 (2H, m, Harom.)
1.35-1.92 (10H, m, cyclopentane), 2.71 (2H, s, imide), 6.54 (1H, d, Harom.,
X 2-CF3 J= 8.20 Hz), 6.59 (1H, brs, -NH-), 7.02 (1H, t, Harom., J=7.56 Hz), 7.38
(1H, t, Harom., J=7.56 Hz), 7.55 (1H, d, Harom., J=7.95 Hz)
Table 3. 1H NMR spectral data of compounds XI-XV
No. R 1H NMR δ (ppm)/ CDCl3 
0.82 (3H, d, -CH3, J=6.67 Hz), 1.00-1.94 (8H, m, cyclohexane), 2.00-2.12 (1H,
m, cyclohexane), 2.48 (1H, d, imide, J=18.72 Hz), 2.71 (1H, d, imide, J=18.72
XI H
Hz), 6.11 (1H, brs, -NH-), 6.76-6.79 (2H, m, Harom.), 6.98 (1H, t, Harom., 
J=7.43 Hz), 7.21-7.26 (2H, m, Harom.)
0.84 (3H, d, -CH3, J=6.67 Hz), 1.00-1.94 (8H, m, cyclohexane), 2.00-2.16 (1H,
m, cyclohexane), 2.35 (3H, s, -CH3), 2.49 (1H, d, imide, J=18.72 Hz), 2.72 (1H,
XII 2-CH3 d, imide, J=18.72 Hz), 6.04 (1H, brs, -NH-), 6.49 (1H, d, Harom., J=7.69 Hz),
6.86-6.91 (1H, m, Harom.), 7.07-7.25 (2H, m, Harom.)
0.82 (3H, d, -CH3, J=6.67 Hz), 1.00-1.93 (8H, cyclohexane), 2.00-2.09 (1H, m, 
cyclohexane), 2.27 (3H, s, -CH3) 2.48 (1H, d, imide, J=18.46 Hz), 2.70 (1H, d,
XIII 3-CH3 imide, J=18.46 Hz), 6.07 (1H, brs, -NH-), 6.55-6.58 (2H, m, Harom.), 6.77-6.80
(1H, m, Harom.), 7.11 (1H, t, Harom., J=7.56 Hz)
0.80 (3H, d, -CH3, J=6.67 Hz), 0.99-1.98 (8H, m, cyclohexane), 2.00-2.09 (1H,
m, cyclohexane), 2.26 (3H, s, -CH3), 2.46 (1H, d, imide, J=18.46 Hz), 2.68 (1H,
XIV 4-CH3 d, imide, J=18.46 Hz), 6.05 (1H, brs, -NH-), 6.69-6.72 (2H, m, Harom.), 7.02-
7.05 (2H, m, Harom.)
0.86 (3H, d, -CH3), J=6.67 Hz), 0.97-1.95 (8H, m, cyclohexane), 2.02-2.14 (1H,
m, cyclohexane), 2.52 (1H, d, imide, J=18.72 Hz), 2.74 (1H, d, imide, J=18.72
XV 2-CF3 Hz), 6.57 (1H, d, Harom., J=8.72 Hz), 6.60 (1H, brs, -NH-), 7.02 (1H, t,
Harom., 7.31 Hz), 7.36 (1H, t, Harom., J=7.82 Hz), 7.55 (1H, d, Harom.,
J=7.95 Hz)
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Table 4. 1H NMR spectral data of compounds XVI-XVIII
No. R 1H NMR δ (ppm)/ CDCl3
1.03-1.78 (10H, m, cyclohexane), 1.97-2.17 (1H, m, cyclohexane), 2.60-2.92
XVI H (3H, m, imide), 6.10 (1H, brs,-NH-), 6.75-6.79 (2H, m, Harom.), 6.98 (1H, t,
Harom., J=7.30 Hz), 7.21-7.26 (2H, m, Harom.)
1.04-1.79 (10H, m, cyclohexane), 1.97-2.06 (1H, m, cyclohexane), 2.34 (3H, s,
XVII 2-CH3 -CH3), 2.61-2.93 (3H, m, imide), 6.02 (1H, brs, -NH-), 6.46-6.49 (1H, m, 
Harom.), 6.86-6.91 (1H, m, Harom.), 7.08-7.12 (2H, m, Harom.)
1.02-1.81 (10H, m, cyclohexane), 1.95-2.17 (1H, m, cyclohexane), 2.26 (3H, s,
XVIII 4-CH3 -CH3), 2.58-2.91 (3H, m, imide), 6.04 (1H, brs, -NH-), 6.68-6.73 (2H, m,
Harom.), 7.02-7.05(2H, m, Harom.)
Table 5. Anticonvulsant screening project (ASP) phase I test in mice of compounds III-X
Dose MESa sc.Metb Toxc ASPd
No. mg/kg 0.5h 4h 0.5h 4h 0.5h 4h Class
30 0/1 0/1 0/1 0/1 1/4 0/2
III 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IV 100 0/3 0/1 0/1 0/1 0/8 0/4 2
300 1/1 0/3 0/1 0/1 1/41 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
V 100 0/3 0/3 0/1 0/1 1/8 0/4 2
300 0/1 0/1 3/52 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VI 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 4/52 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VII 100 0/3 0/3 0/1 0/1 0/8 0/4 3
100 0/1 0/1 0/1 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VIII 100 0/3 0/3 0/1 0/1 4/8 1/4 2
300 1/1 0/1 0/1 5/52 0/1 2/41 0/2
30 0/1 0/1 1/52 0/1 0/4 0/2
IX 100 0/3 0/3 0/1 0/1 1/8 0/4 1
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
X 100 0/3 0/3 0/1 0/1 2/8 0/4 3
300 0/1 0/1 0/1 0/1 2/41 0/2
a) Maximal electroshock test (number of animals protected/ number of animals tested); b) Subcutaneous metrazole test; c) Rotorod toxicity
(number of animals exhibiting toxicity/ number of animals tested);d)The classification are as follows: anticonvulsant activity at doses 100
mg/kg or less (calss 1); anticonvulsant activity at doses greater than 100 mg/kg (class 2); compound inactive at 300mg/kg (class 3).
Response comments: 1 unable to grasp rotorod, 2 myoclonic jerks, 3 tremors
pletely removed, the temperature of the reaction
mixture was raised up to 180OC and maintained for
1.5 h. The crude products were crystallized from
isopropanol. The obtained solid residues were puri-
fied by column chromatography on Silica gel 60
(Merck, Darmstadt, Germany) using chloroform:
acetone mixture (9:1, v/v) as an eluent. After evapo-
ration of the solvents, the oily products were recrys-
tallized from isopropanol. Physicochemical data,
yields, elemental analysis and R] values are present-
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ed in Table 1. 1H NMR spectral data are shown in
Tables 2, 3 and 4.
PHARMACOLOGY
All obtained compounds were pharmacologi-
cally pre-evaluated within the Antiepileptic Drug
Development (ADD) program (Epilepsy Branch,
Neurological Disorders Program, National Institute
of the Neurological and Communicative Disorders
and Stroke (NINCDS), Bethesda), by use of testing
procedures which have been described elsewhere
(13, 14). Phase I studies of the investigated com-
pounds involved three tests: maximal electroshock
(MES), subcutaneous metrazole (sc. Met) and
rotorod test for neurological toxicity (TOX). All the
compounds were injected intraperitoneally to mice,
as a suspension in 0.5% methylcellulose, at the dose
levels of 30, 100, and 300 mg/kg. The compounds
were classified into following categories: anticon-
vulsant activity at 100 mg/kg or less (class 1), anti-
convulsant activity at doses greater than 100 mg/kg
(class 2) and compounds inactive at 300 mg/kg
(class 3). The results are shown in Tables 5 and 6. 
RESULTS
The maximal electroshock (MES) and subcuta-
neous metrazole (sc. Met) tests are claimed to detect
compounds affording protection against generalized
tonic-clonic seizures and generalized absence
seizures, respectively. Thus the MES and sc. Met
screens have become the most widely employed
seizure models for early identification of candidate
anticonvulsants.
The compounds investigated revealed diversi-
fied anticonvulsant properties (Tables 5 and 6).
Except for compounds IV and XI, effective
only in the MES test at a dose of 300 mg/kg (1/1 ani-
mals protected at 0.5 h), all other derivatives showed
protection especially in sc. Met screen. The most
active N-(3-methylphenyl)-amino-2-azaspiro[4.5]
decane-1,3-dione [VIII] inhibited both the metra-
zole (5/5 animals protected at 0.5 h) and electrically
Table 6. Anticonvulsant screening project (ASP) phase I test in mice of compounds XI-XVIII
Dose MESa sc.Metb Toxc ASPd
No. mg/kg 0.5h 4h 0.5h 4h 0.5h 4h Class
30 0/1 0/1 0/1 0/1 0/4 0/2
XI 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 0/1 0/1 3/43 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XII 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 1/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 1/4 1/2
XIII 100 0/3 0/3 0/1 0/1 4/8 1/4 3
300 0/1 0/1 3/52 0/1 3/4 0/2
30 0/1 0/1 1/52 0/1 0/4 0/2
XIV 100 0/3 0/3 0/1 0/1 3/8 0/4 1
300 0/1 0/1 1/12 0/1 2/4 1/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XV 100 0/3 0/3 0/1 0/1 0/8 0/4 1
300 0/1 0/1 0/1 0/1 2/4 2/2
30 0/1 0/1 0/1 1/12 0/4 0/2
XVI 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 1/1 0/1 1/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XVII 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 1/12 0/1 3/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XVIII 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 3/4 0/2
a), b), c), d) and response comments see Table 5.
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provoked (1/1 animals protected at 0.5 h) seizures at
a dose of 300 mg/kg, whereas its 6-methyl analogue
[XIII] was inactive. The comparable results were
obtained for N-(4-methylphenyl)-amino-2-aza-
spiro[4.4]nonane-1,3-dione [V], which protected 3/5
animals at a dose of 300 mg/kg in the sc. Met screen.
The change of the size of a cycloalkyl unit to cyclo-
hexane [IX], as well as introduction of the methyl
group into position-6 [XIV] decreased the anticon-
vulsant activity. Both IX and XIV revealed only
marginal protection at doses of 30 mg/kg (1/5 ani-
mals protected at 0.5 h), however, according to the
procedures of Anticonvulsant Drug Development
Program were ascribed to 1 ASP class. Compound
XIV was also effective at a dose of 300 mg/kg (1/1
animal protected at 0.5 h). 
As had been reported previously (8), the pres-
ence of the trifluoromethyl substituents at position-
2 of the aryl ring attached to the imide nitrogen
atom, directly or through the -CH2- linker, proved to
enhance the anticonvulsant activity. However, in the
present study only N-(2-trifluoromethylphenyl)-
amino-2-azaspiro[4.4]nonane-1,3-dione [VI] show-
ed the anti-sc. Met activity at a dose of 300 mg/kg
(4/5 animals protected at 0.5 h). The enlargement of
size of the cycloalkyl unit to cyclohexane [X] as
well as introduction of the methyl group into 6-posi-
tion [XV] yielded an inactive compound X and
derivative XV, that revealed protection only at a
dose of 30 mg/kg (1/1 animal protected at 0.5 h),
without activity at doses of 100 mg/kg and 300
mg/kg. Surprisingly enough, all the 2-CH3 ana-
logues [III, VII, XII] were found to be inactive. It
was in contrary to earlier experiments indicating that
the presence of this substituent at the position-2 of
the aryl ring is important for the anticonvulsant
activity (6-8, 15). 
To evaluate the role of the cycloalkyl fragment
attached to the C3 spiro carbon atom in aspect of
influence on anticonvulsant activity of spirosuccin-
imides described above, a series of 3-cyclohexyl-
pyrrolidine-2,5-diones [XVI-XVIII] has been syn-
thesized. These molecules were designed as ana-
logues of respective active or inactive spirosuccin-
imides. The obtained results revealed that the intro-
duction of the cyclohexyl moiety as a flexible frag-
ment at 3-position of the imide ring decreased the
anticonvulsant efficacy. Moreover, in opposite to
the data observed for azaspiranes, in this series only
derivative XVII with the methyl group at 2-position
of the aryl moiety inhibited the sc. Met seizures at a
dose of 300 mg/kg (1/1 animal protected at 0.5 h),
whereas 4-CH3 analogue [XVIII] as well as unsub-
stituted compound [XVI] were found to be inactive.
In the neurotoxicity screen only compounds
XII and XVI were devoid of toxicity at the maxi-
mum administrated dose (300 mg/kg). The other
derivatives were found to be neurotoxic at a dose of
30 mg/kg [III, XIII], 100 mg/kg [V, VIII-X, XIII,
XV] and 300 mg/kg [IV-VIII, X, XI, XIII-XV,
XVII, XVIII]. The mice were unable to grasp
rotorod after administration of compounds IV, VIII
and X (300 mg/kg at 0.5 h). All the compounds
effective in the sc. Met test induced myoclonic jerks
at a dose at which the anticonvulsant activity was
demonstrated.
In conclusion, the results obtained, revealed 
that a number of novel N-phenylamino derivatives
of spirosuccinimides were moderately effective
especially in sc. Met screen, however, none of
them was more potent than unsubstituted N-phenyl-
amino-2-azaspiro[4.4]nonane-1,3-dione [I], used
as a lead structure. The activity of those com-
pounds depended on kind and position of sub-
stituents at the aryl moiety as well as the size and
manner of attachment of the cyclolkyl system at
the position-3 of the pyrrolidine-2,5-dione ring. In
general, the methyl groups in position-3 or -4
increased anticonvulsant activity, whereas the
ortho isomers were found inactive. The introduc-
tion of the trifluoromethyl group, which is known
as bioactive structural element (8,16), did not
improve anticonvulsant properties significantly.
Furthermore, the most active were compounds with
cyclopentane unit at the C3 spiro carbon, whereas
the enlargement of size of the cycloalkyl system to
cyclohexane, as well as the presence of additional
methyl group at position-6 decreased anticonvul-
sant efficacy. The comparison of the results
obtained for the spirosuccinimides and compounds
with cyclohexyl moiety as a flexible fragment at
position-3 of the imide ring, proved an essential
role of cycloalkyl system attached through the C3
spiro carbon atom for the anticonvulsant activity of
that type of compounds.
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